

August 1, 2018

Ref: Stock-Exchange/2018-19

Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Mr. Hari K
Asst. Vice President – Operations
National Stock Exchange of India Ltd
Exchange Plaza, Bandra – Kurla Complex
Bandra (East), Mumbai – 400 051

Dear Sir,

Ref: BSE Scrip Code -506690 : NSE Symbol - UNICHEMLAB

Sub: Successful US FDA inspection of API manufacturing facility at Pithampur,

Madhya Pradesh

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please be informed that the Company's API manufacturing facility at Pithampur, Madhya Pradesh was inspected by US FDA from July 23rd to July 27th, 2018. Four observations were made which do not impact continuity of the Company's business and its manufacturing activity. The Company proposes to respond to these observations within 15 business days.

The Pithampur facility manufactures API for use in the production of formulations that are exported to the USA.

Please take this on record.

Thank you,

Yours Faithfully,

a. a. N

For UNICHEM LABORATORIES LIMITED

NEEMA THAKORE

Head - Legal & Company Secretary